Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 5/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4951135 | 0.84 | BACE1 (0.42) | CNR1CNR2BACE1TSHRPTPN11 | |
| SCHEMBL11444986 | 0.83 | KCNH2 (0.46) | KCNH2GRM5CNR1CNR2PTGDR2 | |
| SCHEMBL11324364 | 0.81 | CYP3A4 (0.45) | KCNH2GRM5LMNATSHRFFAR1 | |
| SCHEMBL4448140 | 0.78 | KCNH2 (0.61) | KCNH2GRM5PTGDR2LMNATSHR | |
| SCHEMBL30707788 | 0.78 | KCNH2 (0.61) | KCNH2GRM5PTGDR2LMNATSHR | |
| SCHEMBL29095907 | 0.76 | KCNH2 (0.40) | KCNH2GRM5CNR1CNR2PTGDR2 | |
| SCHEMBL2462120 | 0.75 | KCNH2 (0.53) | KCNH2GRM5PTGDR2LMNATSHR | |
| SCHEMBL29994303 | 0.75 | KCNH2 (0.53) | KCNH2GRM5PTGDR2LMNATSHR | |
| SCHEMBL6045429 | 0.74 | BACE1 (0.38) | BACE1PTPN11 | |
| SCHEMBL13597755 | 0.74 | GRM5 (0.42) | GRM5BACE1PTGDR2PTPN11HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4094995-A | ETHYNYLBENZENE COMPOUNDS AND DERIVATIVES THEREOF TO TREAT PAIN, FEVER AND INFLAMMATION | WILLIAM H. RORER, INC. (US) | 1978-06-13 | — | — | US | claimed |
| EP-2094810-B1 | ORGANIC ELECTROLUMINESCENT DEVICE AND INDOLE DERIVATIVE | UDC IRELAND LTD (IE) | 2017-08-09 | — | — | EP | disclosed |
| EP-2094810-B1 | ORGANIC ELECTROLUMINESCENT DEVICE AND INDOLE DERIVATIVE | UDC IRELAND LTD (IE) | 2017-08-09 | — | — | EP | disclosed |
| US-8283476-B2 | Transition metal catalyzed synthesis of 2H-indazoles | SANOFI (FR) | 2012-10-09 | — | — | US | disclosed |
| EP-2170833-B1 | A TRANSITION METAL CATALYZED SYNTHESIS OF 2H-INDAZOLES | SANOFI AVENTIS (FR) | 2011-06-01 | — | — | EP | disclosed |
| US-20100234601-A1 | Transition metal catalyzed synthesis of 2H-indazoles | SANOFI-AVENTIS (FR) | 2010-09-16 | — | — | US | disclosed |
| EP-2170833-A1 | A TRANSITION METAL CATALYZED SYNTHESIS OF 2H-INDAZOLES | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | disclosed |
| US-20100066243-A1 | ORGANIC ELECTROLUMINESCENT DEVICE AND INDOLE DERIVATIVE | FUJIFILM CORPORATION (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100066243-A1 | ORGANIC ELECTROLUMINESCENT DEVICE AND INDOLE DERIVATIVE | FUJIFILM CORPORATION (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
| US-4150148-A | NITROSUBSTITUTED | WILLIAM H. RORER, INC. (US) | 1979-04-17 | — | — | US | disclosed |
| US-4120889-A | Cyano ethynylbenzene compounds | WILLIAM H. RORER, INC. (US) | 1978-10-17 | — | — | US | disclosed |
| US-4120885-A | Ethynylbenzene compounds and derivatives thereof | WILLIAM H. RORER, INC. (US) | 1978-10-17 | — | — | US | disclosed |
| US-4105786-A | ANTIINFLAMMATORY | WILLIAM H. RORER, INC. (US) | 1978-08-08 | — | — | US | disclosed |
| US-4101591-A | Ethynylbenzene compounds and derivatives thereof | WILLIAM H. RORER, INC. (US) | 1978-07-18 | — | — | US | disclosed |
| US-4096279-A | Ethynylbenzene compounds and derivatives thereof in the treatment of pain fever and inflammation | WILLIAM H. RORER, INC. (US) | 1978-06-20 | — | — | US | disclosed |
| US-4094995-A | ETHYNYLBENZENE COMPOUNDS AND DERIVATIVES THEREOF TO TREAT PAIN, FEVER AND INFLAMMATION | WILLIAM H. RORER, INC. (US) | 1978-06-13 | — | — | US | disclosed |
| US-4093737-A | Ethynylbenzene compounds and derivatives thereof in the treatment of pain, fever or inflammation | WILLIAM H. RORER, INC. (US) | 1978-06-06 | — | — | US | disclosed |
| US-4075354-A | ETHYNYLBENZENE COMPOUNDS AND DERIVATIVES THEREOF FOR TREATING PAIN FEVER AND INFLAMMATION | WILLIAM H. RORER, INC. (US) | 1978-02-21 | — | — | US | disclosed |
| US-3981932-A | Ethynylbenzene compounds and derivatives thereof | WILLIAM H. RORER, INC. (US) | 1976-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | KCNH2 767/4885GRM5 1/4885CNR1 135/4885 |
| US-20100234601-A1 | Transition metal catalyzed synthesis of 2H-indazoles | H1-3, H1-2, H1-4 | KCNH2 41/4885GRM5 4049/4885CNR1 2188/4885 |
| US-20100066243-A1 | ORGANIC ELECTROLUMINESCENT DEVICE AND INDOLE DERIVATIVE | IDO1, IDO2, L1CAM | KCNH2 51/4885GRM5 1858/4885CNR1 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.